The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

A group of Canadian undergrads is using plants to revolutionize medicine. Faced with soaring drug prices and global shortages ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.

Equinox's GLP-1 protocol is considered a framework for people taking the drugs, one that addresses workout intensity, ...